Interferon Product description The Competitive Intelligence Report Interferon as of November 2008 provides a competitor analysis in the development pipeline of novel recombinant and natural interferon alpha, beta, gamma and of other subtypes for treatment of infectious diseases, cancer and multiple sclerosis, respectively. Total sales of the major interferon alpha, beta and gamma products in 2007 were in excess of US$ 7.2 bln, the majority (US$ 4.6 bln) attributable to beta interferons for treatment of multiple sclerosis. While manufacturers of 1st generation interferon alpha successfully have converted their interferon alpha sales into those of 2nd generation pegylated products, no second generation interferon beta products are in the clinical stage pipeline of any company. The field of beta interferon is far less crowded than that of interferon alpha, despite a nearly two-fold higher market size. This would offer a great opportunity for biosimilar (biogeneric) versions of 1st generation interferon beta products, but surprisingly clinical stage drug candidates are scarce despite numerous preclinical stage projects. In contrast, a huge number of different 1st generation interferon alpha products are produced and marketed in off-patent countries. Quite a number of new developments of long-acting or oral interferon alpha products are in development and will compete with pegylated interferons of established manufacturers Roche and Schering-Plough. The report describes the market size of the major type interferon products, provides information on the marketed interferon preparations and includes a compilation of current active projects in research and development of novel interferon products. Competitor projects are listed in a tabular format providing information on: - Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index Interferon Sales 2007 Interferon alpha: - 1st generation IFN alpha-2a
- 1st generation IFN alpha-2a biosmilars and off-patent country products
- 2nd generation IFN alpha-2a
- 2nd generation IFN alpha-2a biosimilars and off-patent country products
- 1st generation IFN alpha-2b
- 1st generation IFN alpha-2b biosimilars and off-patent country products
- 2nd generation IFN alpha-2b
- 2nd generation IFN alpha-2b biosimilars and off-patent country products
- IFN alpha-2b new developments
- Other alpha IFN
- Not specified alpha IFN
Interferon beta: - 1st generation IFN beta-1a
- 1st generation IFN beta-1a biosimilars and off-patent country products
- 1st generation IFN beta-1b
- 1st generation IFN beta-1b biosimilars and off-patent country products
- Other beta IFN
- Not specified beta IFN
Interferon gamma
Other Interferons
Interferons delivered by DNA
Interferons as part of Vaccines
About La Merie Corporate Interferon Product Portfolio and R&D Pipelines: - Abraxis Bioscience
- Advanced Protein Technologies (APTECH)
- Aegis Therapeutics
- Alfa Wassermann
- Alios BioPharma
- Amarillo Biosciences
- Ambrx
- Amega Biotech
- Anhui Anke Biotechnology
- Asterion
- Asubio Pharma
- Axxo
- Barofold
- Bayer Schering Pharma & Berlex
- Bio Sidus
- Bio-Manguinhos
- Biogen Idec
- BioGeneric Pharma
- Biolex
- Bioorganic Research and Services (Bionaturis)
- Biopartners (Bioton)
- BioSante Pharmaceuticals
- Bolder BioTechnology
- Cinnagen
- CJ Corporation
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Digna Biotech
- Dong-A Pharmaceuticals
- Egis Pharmaceuticals & Trigon Biotechnology
- Flamel Technologies
- Genexine
- GenOdyssee
- Green Cross
- HanAll Pharmaceutical
- Hanmi Pharmaceutical
- Heber Biotec
- Helix BioPharma
- Human Genome Sciences
- Ichor Medical Systems
- InSight Biopharmaceuticals
- Intarcia Therapeutics
- Intas Pharmaceuticals
- InterMune
- Intranasal Technology
- Kee Pharma
- Laboratorios Cryopharma
- Lipoxen
- LG Life Sciences
- Merck Serono
- Mochida Pharmaceutical Co.
- Modigene
- MolMed
- Nanogen Biopharmaceuticals
- Nautilus Biotech
- Novartis
- Otsuka Pharmaceutical Co.
- PBL Therapeutics
- Phage Biotechnology
- PharmaEssentia
- Probiomed
- Proxima Concepts (Kancer Ltd.)
- Reliance Life Sciences & Reliance GeneMedix
- Rhein-Minapharm Biogenetics
- RioTech Pharma
- Roche
- Schering-Plough
- Shantha Biotechnics
- Shenyang Sunshine Pharmaceutical Co
- Shenzhen Kexing Biotech
- Shire
- Sudershan Biotech
- Swedish Orphan
- Synairgen
- Teva Pharmaceutical Industries (CoGenesys & Sicor Biotech)
- Therapeutic Proteins Ltd.
- Three Rivers Pharmaceuticals
- Tinajin Hualida Biotechnology
- Toray
- Transgene
- Transgene Biotek
- USV Ltd (India)
- Vakzine Projekt Management
- Virax Holdings
- Wockhardt
- Zenotech Laboratories
- Zymogenetics
About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are independently elaborated by analysts of La Merie Business Intelligence and distributed by PipelineReview.com.
|
